Clinical Trial Update: Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers [Phase 1]

View source ↗

Summary

A Phase 1 study investigated whether atorvastatin (Lipitor) can decrease panel reactive antibody titers in end-stage kidney disease; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Kidney Disease

Drugs mentioned

• Lipitor (atorvastatin)

Snippet

Sponsor: University of Chicago | Conditions: End-Stage Kidney Disease | Phase 1 | Status: COMPLETED